<div><p>Mutations in <i>BRCA1</i> and <i>BRCA2</i> are responsible for a large proportion of breast-ovarian cancer families. Protein-truncating mutations have been effectively used in the clinical management of familial breast cancer due to their deleterious impact on protein function. However, the majority of missense variants identified throughout the genes continue to pose an obstacle for predictive informative testing due to low frequency and lack of information on how they affect BRCA1/2 function. Phosphorylation of BRCA1 and BRCA2 play an important role in their function as regulators of DNA repair, transcription and cell cycle in response to DNA damage but whether missense variants of uncertain significance (VUS) are able to disrupt ...
<div><p>The identification of variants of unknown clinical significance (VUS) in the <i>BRCA1</i> ge...
BACKGROUND: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with i...
Unambiguous classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) is a challeng...
Mutations in BRCA1 and BRCA2 are responsible for a large proportion of breast-ovarian cancer familie...
Mutations in BRCA1 and BRCA2 are responsible for a large proportion of breast-ovarian cancer familie...
<p>In <b>bold</b> are BRCA1 mutations that fall within an experimentally identified but biologically...
<p>In <b>bold</b> are BRCA1 mutations that directly mutate an experimentally identified phosphorylat...
Background: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with i...
Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often...
Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often...
International audienceBRCA1 mutations have been identified that increase the risk of developing here...
<div><p>Germline inactivating variants in <i>BRCA1</i> lead to a significantly increased risk of bre...
<div><p>The identification of variants of unknown clinical significance (VUS) in the <i>BRCA1</i> ge...
BACKGROUND: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with i...
Unambiguous classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) is a challeng...
Mutations in BRCA1 and BRCA2 are responsible for a large proportion of breast-ovarian cancer familie...
Mutations in BRCA1 and BRCA2 are responsible for a large proportion of breast-ovarian cancer familie...
<p>In <b>bold</b> are BRCA1 mutations that fall within an experimentally identified but biologically...
<p>In <b>bold</b> are BRCA1 mutations that directly mutate an experimentally identified phosphorylat...
Background: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with i...
Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often...
Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often...
International audienceBRCA1 mutations have been identified that increase the risk of developing here...
<div><p>Germline inactivating variants in <i>BRCA1</i> lead to a significantly increased risk of bre...
<div><p>The identification of variants of unknown clinical significance (VUS) in the <i>BRCA1</i> ge...
BACKGROUND: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with i...
Unambiguous classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) is a challeng...